The most common classification of heart failure currently in use stratifies patients into Heart failure with reduced ejection fraction ("systolic HF") Heart failure with preserved ejection fraction ("diastolic HF") Heart failure with mildly reduced ejection fraction Heart failure with reduced ejection fraction (HFrEF) In HFrEF standard of care includes the following four classes of therapies, considered to be 'foundational therapies' for HFrEF management: Beta-blocker Renin-angiotensin-aldosterone system (RAAS) inhibitor (typically an ARNI, although an ACE inhibitor or ARB could also used if ARNI is not tolerated) Aldosterone antagonist SGLT2 These four drug classes have been studied and have shown benefit for long-term management of HFrEF.